Agenda of April 2017 Conference (RWE)

http://www.eyeforpharma.com/real-world-evidence/conference-agenda.php?elqTrackId=74a54b7e2c6d4cd1957d49e5d8a9aead&elqaid=16957&elqat=2

Day One

• 08:15-09:00	Registration
  09:00-09:05	Opening Address
  Reg Waldeck VP Access, Pricing and HE Celldex
  09:05-09:35	Work cross-functionally to unlock new insights throughout the lifecycle
  Adopt a cross-functional approach, enabling increased real-world understanding from discovery to post-approval Understand how different teams can work together to break data silos, enhancing the internal spread of knowledge Meet increasing regulatory requirements by engraining a continuous cycle of evidence generation into your company’s core efforts
  Michael Seewald Global Head of Real World Evidence Novartis
  09:35-10:00	Insights, Ecosystems, and Outcomes: Using Data to Drive Value Based, Personalised Healthcare
  Understand how the healthcare ecosystem is undergoing an unprecedented period of change Explore how life science organisations are investing in end to end evidence approaches which require new operating models and technology choices Industry Case Study - Implementing an enterprise wide RWE strategy
  Brett Davis General Manager, Converge HEALTH Deloitte Sebastien Burnett Director Deloitte
  10:00-10:25	Make sure your product is launch ready by integrating market access into drug discovery and development
  Use payer insights to tailor clinical trial design to ensure the data collected meets market requirements How to promote market access priorities in phase II and III to ensure a seamless, HTA-ready launch Explore ways to engage payers early in order to evade potential pitfalls and hurdles to reimbursement
  Barbara Jaszewski VP Global Pricing and Market Access Lundbeck
  10:25-10:55	Coffee break
  10:55-11:35	Panel discussion: Emerging data sources – meet evolving data needs with the latest innovations
  Discover the increased patient insight offered by previously under-utilised data sources Meet increased HTA/payer demands with increased value demonstration Learn how to maximise analytical capabilities by harmonising data collection across multiple platforms
  Martin Price VP Health Economics & Market Access Janssen Patrick Hopkinson Executive Director WWHEOR Markets BMS Michael Seewald Global Head of Real World Evidence Novartis Chair: Anne-Toni Rodgers Global Head Operations Payer & Real World Evidence AstraZeneca
  11:35-12:00	Increase product launch success with a cross-functional use of real world evidence.
  Prepare for future product development and launch by integrating RWE across functions (Clinical Development, Medical, Market Access, Marketing) Enhance product understanding and communication with a fluid approach Case example of innovative basal insulin launched in crowded diabetes market place and price containment context
  Tra-Mi Phan VP Medical & Scientific Affairs Europe Novo Nordisk
  12:00-12:25	External collaboration with stakeholders to optimize patients access strategies “from clinical development to patient access”
  Understand the principles of market access and medical teaming up to shape patients outcomes in unmet haematological malignancies Hear how R&D innovation is being accelerated through the nurturing of a ground breaking public-private relationship Genuinely maximise your real-world capability by building your strategy in partnership key stakeholders and competitors
  Pam Bacon Executive Director, Medical Affairs Celgene Tay Salimullah Global Pricing & Market Access Director Novartis
  12:25-12:50	Driving Market Access with RWE: Rhetoric vs. Reality
  Explore the different perceptions surrounding RWE and optimise your real-world access strategy with greater understanding of the other halves needs Interactive session gauging the audience’s own perceptions on the Market Access/RWE relationship
  Anne-Toni Rodgers Global Head Operations Payer & Real World Evidence AstraZeneca
  12:50-14:00	Lunch Break (New Chair: Agathe Le Lay, Head of HEOR Europe, Novo Nordisk)
  14:00-15:00	Multi-presentation feature: See how IMI’s ‘GetReal’ project is increasing RWE’s practical application with earlier adoption into the lifecycle
  Hear how best to demonstrate effectiveness through real-life clinical studies with thought leadership from stakeholders across healthcare Smoothly incorporate pragmatic trials into your operations with the latest methodological approaches Delve into the range of tools developed from the program accelerating RWE development
  Chris Chinn Head of RWE Strategy for Market Access Sanofi Rob Thwaites Senior Director-Strategy, Global Outcomes Research and Head, GI, Global Outcomes Research Takeda
  15:00-15:30	Lean Clinical Development - Adding value with visual evidence.
  BDD Scintigraphy as a tool to maximise clinical investment Seeing is believing - RWE to support product claims, marketing and strategy Case study; In vivo imaging of novel complex oral product
  Prof. Howard Stevens Chairman bddpharma
  15:30-16:00	Coffee Break
  16:00-16:30	Optimise your clinical trials using Electronic Health Records
  See how the EHR4CR project is increasing patient understanding through the catalyse of EHR use in Europe Enhance your clinical trial efficiencies with RWD protocol data testing, accelerated patient recruitment and enhanced EHR data extraction See how the new ‘Champion Programme’ is reducing the risk of investing in EHRs, encouraging growth of the EHR ecosystem
  Mats Sundgren Principal Scientist, Director, Global Medicines Development AstraZeneca R&D
  16:30-17:00	The Importance of an Integrated Medical Plan
  A review of recent drug launch success Where RWE collection could have played its part Building an Integrated Medical Plan to prepare for success: “Begin with the End in Mind” The “Resource v Demand” Challenge in this environment
  Alastair Macdonald Executive Director, Real World and Late Phase Business Unit INC Research
  17:00-17:30	Why choosing RWD from the right league changes everything.
  What are the different leagues of real world data and how do they change the opportunities for relevant research? Discover why Registry Based Randomized Clinical Trials will be the next disruptive technology in clinical research Value Based Health Care examples based on high quality data sets
  Mattias Kyhlsedt CEO Synergus
  17:30-18:00	Real World Data (RWD) and Real World Evidence (RWE): Turning the myriad of data sources into clinical practice evidence
  Is RWE actually a new trend? Why are we talking so much about it now? Explore the differences, perceived and real, between RWD & RWE Understand the values and risk associated with adopting a real-world approach
  Enkeleida Nikai Director of RWE - Medical Affairs International Eli Lilly
  18:00-19:00	Networking Drinks
  19:00	End of Day One

 GET THE 2017 EVENT BROCHURE NOW

Full speaker list • Full conference agenda • Audience Breakdown

Day Two

• 09:00-09:30	Expand your research capability by utilising CPRD as a tool for innovation
  Explore how the CPRD is evolving to further vary and increase their sources of data, expanding research possibilities Educate clinical trial design to improve clinical output with more targeted patient identification Providing the data for different research purposes in clinical trials
  Janet Valentine Director of the Clinical Research Practice Database CPRD
  09:30-10:00	Unleashing data science in RWE via next generation tools
  Machine learning, deep-learning, phenotyping or tensors can transform RWE  Major barriers exist: lack of skills, using data scientists for simple data management QuintilesIMS discusses case studies and next generation tools to unlock data science
  Robin Murray Director, RWI Technology QuintilesIMS
  10:00-10:30	Draw further insight from your RWD with interactive visualization techniques
  Understand how interactive visualization can help you explore your data in new ways, finding previously undiscovered hypothesis Case study examples surrounding the latest Janssen work in partnership with Karolinska Institute and the Royal Institute of Technology
  Johan Liwing Director Global Market Access RWE Partnerships Janssen
  10:30-11:00	Coffee Break
  11:00-11:45	The GSK Salford Lung Study: Lessons learnt
  Hear how experiences from pioneering pragmatic phase III study can aid in pushing further real-world studies into reality Understand how electronic health records allowed for quick and easy access of patient information – enabling the study to take place  See the way the studies inclusive approach generated greater insight into drug effectiveness in a real-world setting Learn how collaboration with local healthcare providers played a crucial role in the studies effectiveness and operational capacity
  David Leather Medical VP GSK Global Respiratory Franchise & Salford Lung Study Lead Jørgen Vestbo Lead Investigator GSK Salford Lung Study
  11:45-12:15	Innovative approaches to Real World uses of EHR data
  Find out how Ignite are using EHR data to find and consent patients onto studies across the UK Discover how current technology is being utilised to extract data across most UK healthcare settings Understand how some traditional processes can support the use of technology and eSourced data
  Jacqui Brereton Director of Development Ignite Data

• 12:15-13:15 Choose between the following 3 workshops
  Choice 1	Interactive Workshop 1: The role of digital technology in RWD programs
  Explore the use of technology to support patient data capture across observational, pragmatic and commercial health management programs Build in representativeness through use of patient’s own devices Understand how this approach facilitates the capture of high quality, regulatory compliant datasets built for analysis and mining in a real-world setting Discuss how, where applicable, technology can support enhanced patient engagement and improved health outcomes
  Gavin Birchnall Senior Solutions Architect ERT
  Choice 2	Interactive Workshop 2: Market Access - Back to The Future
  In this interactive workshop, we will explore Market Access Reality vs Market Access Ideology, to test the hypothesis that: “To improve post-launch market access success, market access activities must start early in a product’s lifecycle” If the current reality is suboptimal, what opportunities are we missing? If we could go back in time and change what was done, could things have been different - could the challenges have been predicted and addressed?
  Paul Mcloughlin Covance
  Choice 3	Interactive Workshop 3: Maximizing real world data with governance in a digital world
  Gain insights into managing RWD with effective governance to help create tailored programs. This workshop will help you learn how to future proof your data with best practices (acquiring, qualifying and maximizing RWD) Understand the challenges of acquiring data with a real-life case study of how pharma organizations are filling the gaps on their own compliance practices Explore how RWD can be used to create an effective patient/HCP journey and analyse the campaign performance
  Mitesh Chavda Account Director Epsilon

• 13:15-14:15	Lunch Break
  14:15-14:45	The Patient Perspective: Real World Evidence = Real World Patients: Design your real-world strategy around the key stakeholder
  Hear how to work with patients in your real-world set-up to change attitudes toward data collection; improving your collection techniques and results Explore the opportunities social media offers for patient engagement and data collection Understand why the strive for a patient-centric pharma does not exclude big data
  Alan Thomas Founder Ataxia & Me
  14:45-15:15	Real World Evidence: who cares? Investigating how EU payers actually base decisions on RWE
  Address increasing evidence expectations from EU payers by exploring their usage of RWE in HTA and reimbursement decisions Assess EU payer receptiveness and future trends for RWE, to build buy-in from partner functions for RWE investment Share selected learnings on how industry leaders can use RWE for positive impact on payer decisions.
  Gavin Outteridge Vice President Kinapse Korina Papadopoulou Manager Kinapse
  15:15-15:45	Increase your understanding of the burden of illness through text mining
  Break the traditional feedback model to discover new findings from the analysis of open-ended patient feedback Explore how text mining advancements are expanding the traditional scope of data analysis
  Asif Khan Associate Director, Global HEOR Sanofi
  15:45-17:00	Coffee to stay or go